Vx 001

Drug Profile

Vx 001

Alternative Names: hTERT572Y/hTERT572; Human telomerase reverse transcriptase 572Y; TERT572Y; Vx-001; Vx-001/hTERT

Latest Information Update: 05 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vaxon Biotech
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Jan 2018 Vx 001 is still at phase II development stage for Non-small cell lung cancer in Czech Republic, France, Germany, Greece, Italy, Poland, Romania and Spain (SC) (Vaxon Biotech pipeline, January 2018)
  • 07 Sep 2015 Vx 001 is still in phase II trials for Non-small cell lung cancer in Greece
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top